Stathopoulos G, Papakostas P, Malamos N, Samelis G, Moschopoulos N
UNIV ATHENS,HIPPOKRATION HOSP,DEPT ONCOL,MED DIV 2,GR-10679 ATHENS,GREECE.
Oncol Rep. 1996 Jul;3(4):673-6. doi: 10.3892/or.3.4.673.
Forty patients with non-small cell lung cancer stage IIIA, aged 33-72 years were allocated to two groups in order to get therapy of two different combined modalities. All the patients were staged and considered inoperable. Staging was done by bronchoscopy, CT scan, bone scan and in patients with mediastinal lymph nodes less than 2 cm in size by thoracotomy. Group A patients were programmed to have induction chemotherapy and then radiotherapy while patients of group B to have induction chemotherapy, of the same kind as Group A and then surgery. Chemotherapy included cis-platinum 90 mg/m(2) given once every 3 weeks for 4-6 courses. Radiotherapy of Group A patients was 5000 cGy in the primary tumor site and mediastinum. Toxicity was tolerable. The following results were obtained: a) high response rate (over 70%) after chemotherapy, b) 66% of Group B patients were redered operable and c) the survival rate was significantly higher in patients with chemo-surgery versus those with chemo-radiotherapy.
40例年龄在33至72岁之间的IIIA期非小细胞肺癌患者被分为两组，以接受两种不同联合治疗方案。所有患者均已分期且被认为无法手术。分期通过支气管镜检查、CT扫描、骨扫描进行，对于纵隔淋巴结小于2厘米的患者通过开胸手术进行分期。A组患者计划先进行诱导化疗，然后进行放疗，而B组患者先进行与A组相同的诱导化疗，然后进行手术。化疗包括每3周给予顺铂90mg/m²，共4至6个疗程。A组患者在原发肿瘤部位和纵隔的放疗剂量为5000cGy。毒性是可耐受的。获得了以下结果：a）化疗后高缓解率（超过70%），b）B组66%的患者可再次进行手术，c）接受化疗-手术的患者生存率明显高于接受化疗-放疗的患者。
